Break it Down: BlinkLab’s positive pivot into US market path
Stockhead TV’s Sarah Hughan brings you today’s Break it Down, detailing the positive outcome from the US Food and Drug Administration from BlinkLab.
Stockhead's Break it Down brings you today's leading market news in under 90 seconds.
In this episode, host Sarah Hughan tells all on Blinklab's (ASX:BB1) step towards FDA approval for its autism diagnostic app after receiving certain confirmation from the US food and drug administration.
According to the country’s CDC, 1 in 36 children in America have autism spectrum disorder.
Tune in to get the latest.
While BlinkLab is a Stockhead advertiser, it did not sponsor this content.
Originally published as Break it Down: BlinkLab’s positive pivot into US market path
ASX up, Appen and Novonix race ahead
The ASX rallied on commodities boost on December 27. BrainChip and DroneShield led, while 2025 volatility looms with key risks.
Gold M&A on the cards
With two juniors entering trading halts, more gold M&A could be coming in 2024. With prices near record highs, 2025 looks even wilder.
Japan joins mission critical
The owner of a fluorspar deposit in northern WA says Japan’s Sumitomo could take a 22.5% stake in a $60m JV to develop the project.